Has novelty in the depression pipeline hit a wall?

The Phase III failure of another novel investigational product for depression, Shire's Vyvanse (lisdexamfetamine dimesylate), is raising questions over the health of the pipeline.

The Phase III failure of another novel investigational product for depression, Shire's Vyvanse (lisdexamfetamine dimesylate), is raising questions over the health of the pipeline.

According to BioMedTracker, an affiliate of Scrip, only seven novel drugs have been granted approval for the indication of major...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category